- Home
- SEER vs LSB Comparison
SEER vs LSB Comparison
Compare SEER & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- LSB
- Stock Information
- Founded
- SEER 2017
- LSB 2002
- Country
- SEER United States
- LSB China
- Employees
- SEER N/A
- LSB 758
- Industry
- SEER Medicinal Chemicals and Botanical Products
- LSB
- Sector
- SEER Health Care
- LSB
- Exchange
- SEER Nasdaq
- LSB NYSE
- Market Cap
- SEER 105.0M
- LSB 114.3M
- IPO Year
- SEER 2020
- LSB N/A
- Fundamental
- Price
- SEER $1.69
- LSB $0.75
- Analyst Decision
- SEER Hold
- LSB
- Analyst Count
- SEER 1
- LSB 0
- Target Price
- SEER $3.00
- LSB N/A
- AVG Volume (30 Days)
- SEER 296.7K
- LSB 24.1K
- Earning Date
- SEER 11-05-2024
- LSB 09-24-2024
- Dividend Yield
- SEER N/A
- LSB N/A
- EPS Growth
- SEER N/A
- LSB N/A
- EPS
- SEER N/A
- LSB N/A
- Revenue
- SEER $14,738,000.00
- LSB $79,415,311.00
- Revenue This Year
- SEER N/A
- LSB $39.33
- Revenue Next Year
- SEER $43.19
- LSB $75.61
- P/E Ratio
- SEER N/A
- LSB N/A
- Revenue Growth
- SEER N/A
- LSB N/A
- 52 Week Low
- SEER $1.46
- LSB $0.35
- 52 Week High
- SEER $2.62
- LSB $1.12
- Technical
- Relative Strength Index (RSI)
- SEER 53.32
- LSB 75.76
- Support Level
- SEER $1.59
- LSB $0.44
- Resistance Level
- SEER $1.73
- LSB $0.48
- Average True Range (ATR)
- SEER 0.06
- LSB 0.03
- MACD
- SEER 0.01
- LSB 0.02
- Stochastic Oscillator
- SEER 71.43
- LSB 100.00
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.